Podcast
41 min listening Time

China is changing the world's pharma landscape, with Ruby Wang and Alexander Brown

 

 

China's transformation in biotech and drug development in the last two decades has been dramatic. It has moved from featuring many copycats or generics based on Western assets to now increasingly being a source of novel, high-quality drug assets. Ruby Wang, writer, physician, and biotech consultant, and Alexander Brown, Lead Analyst at MERICS, join Johannes Heller-John to discuss China’s rise in the biotech sector, and what it means for companies, decisionmakers and patients in China and Europe.

Learn more about the topics in this issue here:

Podcast Guest(s)
Avatar Placeholder
Ruby Wang
Writer, physician, and biotech consultant
Podcast Host(s)